Alkermes Reports Orphan Drug Designations For Alixorexton

June 15, 2026 — 07:27 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Alkermes plc (ALKS) announced that alixorexton, an investigational, oral, selective orexin 2 receptor agonist in development for the treatment of narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, was recently granted orphan drug designations from leading regulatory bodies. The FDA has granted orphan drug designation to alixorexton for the treatment of idiopathic hypersomnia. The European Commission has granted orphan drug designation to alixorexton for the treatment of narcolepsy.

Craig Hopkinson, Chief Medical Officer and Executive Vice President, Research & Development at Alkermes, said: "We look forward to continuing our momentum in the alixorexton development program as we enroll the phase 3 Brilliance Studies and work to complete the Vibrance-3 phase 2 study in IH this year."

In pre-market trading on NasdaqGS, Alkermes shares are down 0.18 percent to $44.20.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Alkermes Reports Orphan Drug Designations For Alixorexton

Tags

Latest Articles